BIO Comments on FDA Draft Guidance on Evaluation of Bulk Drug Substances Nominated for Use in Compounding
May 25, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.
Compounded drugs can serve an important role for patients who have clinical needs that cannot be met by an FDA-approved product. Access to medically necessary compounded medicines is important – but access cannot and should not come at the expense of product quality and patient safety.
BIO strongly encourages and supports the FDA’s allocation of resources to enable the safety of compounded drugs. BIO agrees these drugs should only be used by patients whose medical needs cannot be met by an FDA-approved drug. In addition, BIO is pleased to see the FDA discuss the importance of the drug approval process and the need to ensure compounded drugs do not weaken incentives for companies to conduct clinical testing and bring new drugs to market.
In the comments, BIO also discusses issues including the process for nomination and review of the 503B list for bulk compounding, clarification of what constitutes “clinical need,” and non-biologic complex drugs and narrow therapeutic index drugs.
Download Full Comments Below
2018-05-25 BIO Comments On Bulk Drug Substances FINAL
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.
Compounded drugs can serve an important role for patients who have clinical needs that cannot be met by an FDA-approved product. Access to medically necessary compounded medicines is important – but access cannot and should not come at the expense of product quality and patient safety.
BIO strongly encourages and supports the FDA’s allocation of resources to enable the safety of compounded drugs. BIO agrees these drugs should only be used by patients whose medical needs cannot be met by an FDA-approved drug. In addition, BIO is pleased to see the FDA discuss the importance of the drug approval process and the need to ensure compounded drugs do not weaken incentives for companies to conduct clinical testing and bring new drugs to market.
In the comments, BIO also discusses issues including the process for nomination and review of the 503B list for bulk compounding, clarification of what constitutes “clinical need,” and non-biologic complex drugs and narrow therapeutic index drugs.